Liverpool School of Tropical Medicine Confidence in Concept 2013

Lead Research Organisation: Liverpool School of Tropical Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Heinson AI (2017) Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology. in International journal of molecular sciences

publication icon
Ismail HM (2016) Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. in Proceedings of the National Academy of Sciences of the United States of America

 
Description Consultant advisor to the WHO Pre-Qualification Team (PQT) Vector Control
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
URL https://www.who.int/pq-vector-control/about/en/
 
Description EVI European Vaccine Workshop
Geographic Reach Europe 
Policy Influence Type Citation in other policy documents
URL http://www.ncbi.nlm.nih.gov/pubmed/26431986
 
Description External Scientific Advisory Board Member for the German Centre for Infection Research
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description External advice to major funder with regard to antimalarial drug discovery projects 2016 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Invited member of the Expert Scientific Advisory Committee (ESAC) for the "USAID Grand Challenge for prevention of Zika and Future Threats"
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
URL https://www.usaid.gov/grandchallenges/zika
 
Description Macrofilaricide Drug Accelerator (MacDA) 2015 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Member of the MMV External Scientific Advisory Board 2017 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description • UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites" - 2014- to date
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
URL http://www.costcm1307.org/CM1307/Home.html
 
Description African Research Excellenz Fellowship
Amount £36,732 (GBP)
Organisation Medical Research Council (MRC) 
Department Medical Research Foundation
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 11/2018
 
Description BMGF
Amount $3,491,050 (USD)
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 03/2016 
End 12/2017
 
Description Departmental PhD studentship for Rik van der Veen, Nuffield Dept. of Medicine, University of Oxford
Amount £95,430 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description Departmental PhD studentship for Romain Guyon, Nuffield Dept. of Medicine, University of Oxford
Amount £95,430 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description Developing entomological indicators to assess the public health value of next generation LLINs
Amount $3,884,815 (USD)
Funding ID OPP120015 
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 02/2019 
End 07/2022
 
Description Diagnostic tools for poverty-related diseases
Amount € 1,415,000 (EUR)
Organisation Sixth Framework Programme (FP6) 
Department European and Developing Countries Clinical Trials Partnership
Sector Public
Country Netherlands
Start 03/2016 
End 02/2019
 
Description Fundação para o Desenvolvimento Científico e Tecnológico em Saúde (FIOTEC)
Amount $430,097 (USD)
Organisation Centers for Disease Control and Prevention (CDC) 
Sector Public
Country United States
Start 05/2017 
End 05/2018
 
Description GCRF Growing Research Capability
Amount £6,467,378 (GBP)
Organisation Research Councils UK (RCUK) 
Sector Public
Country United Kingdom
Start 04/2017 
End 04/2021
 
Description Industrial funding from QuantuMDx Group Ltd
Amount £101,364 (GBP)
Organisation QuantuMDx Group Limited 
Sector Private
Country United Kingdom
Start  
 
Description Innovate UK
Amount £635,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start  
 
Description Invited grant proposal
Amount $2,000,045 (USD)
Funding ID OPP1159078 
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2017 
End 12/2019
 
Description MRC
Amount £500,000 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC Confidence in Concept Scheme
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 08/2016
 
Description MRC CASE studentship
Amount £104,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2016 
End 01/2020
 
Description MRC CiC Oxford Fund
Amount £51,813 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC Human Nutrition Research Group
Sector Academic/University
Country United Kingdom
Start 02/2017 
End 10/2017
 
Description Pathfinder Award
Amount £98,932 (GBP)
Funding ID 109744/Z/15/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2016 
End 10/2018
 
Description Project Grant
Amount £18,471 (GBP)
Funding ID A1955 
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 02/2019
 
Description St George's Impact & Innovation Award
Amount £15,000 (GBP)
Organisation St George's University of London 
Sector Academic/University
Country United Kingdom
Start  
 
Description UK Public Health Rapid Support Team (UK-PHRST)
Amount £47,500 (GBP)
Organisation Department of Health (DH) 
Sector Public
Country United Kingdom
Start 03/2020 
End 12/2020
 
Description Wellcome Trust Collaborative Award
Amount £2,474,741 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2016 
End 06/2019
 
Title Amplification of antigen-specific memory B cells 
Description Activation and amplification of antigen-specific memory B cells through in vitro culture of memory B cells, autologous T cells and antigen followed by single cell sorting of activated B cells 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact The method is useful when the number of memory B cells specific for a given antigens is low for instance when the volumne of blood available from a volunteer is small or infection occurred several years ago. 
 
Title DDT-Adhiron 
Description DDT binding adhirons developed that can be used to track DDT. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Still in early phase IP protection 
 
Title DDT-Hapten 
Description DDT-hapten; new biotinylated DDT engineered for biopanning 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact Used to isolate DDt-Adhirons, diagnostic for DDT detection in development 
 
Title Recombinant human monoclonal antibodies against the DBLbeta domain of PfEMP1 
Description To date, we generated 6 recombinant monoclonal antibodies recognizing at least 2 different variants of the DBLbeta domain of PfEMP1, which mediates adhesion of P. falciparum infected erythrocytes to ICAM-1. Three of these recombinant antibodies react with at least four different DBLbeta variants and can be considered cross-reactive. Importantly, these antibodies react with the native protein expressed on the surface of infected erythrocytes by flow cytometry and in agglutination assays. 
Type Of Material Antibody 
Provided To Others? No  
Impact The characterisation of recombinant monoclonal antibodies is still in early stages. If one or more of these antibodies reverse adhesion of infected erythrocytes to ICAM-1, their use as an adjunct therapy for severe malaria can be investigated. In addition, both variant-specific and variant-transcending antibodies will be useful tools for other researchers who investigate the biology of or the pathology mediated by expression of PfEMP1 on infected erythrocytes. 
 
Title Staining of antigen-specific B cells using biotinylated tetramers 
Description We developed DBLb and CIDRa1 tetrameric probes to allow the isolation of antigen-specific memory B cells 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The method is more specific for the isolation of antigen-specific memory B cells and reduced time and cost required for screening 
 
Title The evaluation of new antigens for subunit vaccines against Mycobacterium tuberculosis. 
Description The research aims to test the hypothesis that candidate antigens predicted in a previously published reverse vaccinology (RV) approach (Bowman et al., 2011) will exhibit sufficient antigenicity for incorporation into subunit vaccines for Mtb. Additional bioinformatics analyses such as predicted expression and analysis of transmembrane domains were performed in order to generate a short-list of 6 candidate genes which were formulated as DNA vaccines. This was achieved using the Invitrogen Gateway cloning system to insert the genes into a modified pVAX plasmid. After confirmation that the sequence was correct, the plasmids underwent amplification, purification and transfection studies were carried out which proved that the proteins were expressed in eukaryotic (hamster) cell lines. Further quality control checks were also completed (i.e. restriction digests) which confirmed the correct, complete desired sequences had been inserted into the DNA vaccine constructs. The DNA vaccine solutions were then diluted to the appropriate concentration for mouse experiments to evaluate the protective efficacy of the vaccines against Mtb challenge. The first challenge experiment has been completed and compared 6 plasmid DNA vaccines with a BCG vaccinated control group and an untreated group (n=8 per group). Protection was determined by the ability to reduce the number of viable bacteria in the lungs and spleens of animals, measured at 4 weeks post- aerosol challenge with M. tuberculosis. Two of the candidates showed efficacy by reducing the bacterial counts in the lungs compared to the un-vaccinated controls. A repeat study on up to 3 candidates which show protection was initiated in January 2016 for completion in April 2016. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact If the methodology is successful at predicting efficacious vaccine candidates for Mycobacterium tuberculosis the impact will be a research tool which will improve the ability to identify novel vaccine candidates for TB disease and for other important bacterial pathogens. Specifically the TB vaccine candidates identified in this award could be incorporated into suitable delivery systems for further development towards an improved vaccine for TB. 
 
Title Data from: Barrier bednets target malaria vectors and expand the range of usable insecticides 
Description Transmission of Plasmodium falciparum malaria parasites occurs when nocturnal Anopheles mosquito vectors feed on human blood. In Africa, where malaria burden is greatest, bednets treated with pyrethroid insecticide were highly effective in preventing mosquito bites and reducing transmission, and essential to achieving unprecedented reductions in malaria until 2015. Since then, progress has stalled and with insecticidal bednets losing efficacy against pyrethroid-resistant Anopheles vectors, methods that restore performance are urgently needed to eliminate any risk of malaria returning to the levels seen prior to their widespread use throughout sub-Saharan Africa. Here we show that the primary malaria vector Anopheles gambiae is targeted and killed by small insecticidal net barriers positioned above a standard bednet, in a spatial region of high mosquito activity but zero contact with sleepers, opening the way for deploying many more insecticides on bednets than currently possible. Tested against wild pyrethroid-resistant Anopheles gambiae in Burkina Faso, pyrethroid bednets with organophosphate barriers achieved significantly higher killing rates than bednets alone. Treated barriers on untreated bednets were equally effective, without significant loss of personal protection. Mathematical modelling of transmission dynamics predicted reductions in clinical malaria incidence with barrier bednets that exceeded those of 'next-generation' nets recommended by WHO against resistant vectors. Mathematical models of mosquito-barrier interactions identified alternative barrier designs to increase performance. Barrier bednets that overcome insecticide resistance are feasible using existing insecticides and production technology, and early implementation of affordable vector control tools is a realistic prospect. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
 
Title OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens 
Description Background The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made. Methods An internet-based tool has been developed using STELLA® software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds. Results The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies. Conclusions OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies. 
Type Of Material Computer model/algorithm 
Year Produced 2016 
Provided To Others? Yes  
Impact The software has been used by a number of users for both teaching and research purposes. The use of the model has lowered the number of animal experiments in my laboratory but it is difficult to estimate how many in vivo experiments it has reduced externally. We are currently working to promote the on-line tool. 
URL http://optimalpk.lstmed.ac.uk
 
Title Syngenta antimalarial hits 
Description Ongoing Syngenta chemical library being assessed for in vitro anti malarial activity 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Will generate starting points for drug discovery programmes 
 
Title Test performance profiles for chikungunya 
Description We prepared dengue and chikungunya Test Performance Profiles (TPP) and share them with the Partnership for Dengue Control. Please notice there is no option to classify TPPs. 
Type Of Material Data analysis technique 
Year Produced 2015 
Provided To Others? Yes  
Impact Discussion of the TPPs for chikungunya and Zika viruses. 
URL http://www.controldengue.org/
 
Title limits of detection of the Genedrive tuberculosis cartridge 
Description We evaluated the limits of detection of the Genedrive tuberculosis cartridge and reported back to the SME Epistem. 
Type Of Material Data analysis technique 
Year Produced 2014 
Provided To Others? Yes  
Impact This led to epistem changing the design of the cartridge to process a higher volume of sputum to increase the number of bacilli identified. A new cartridge is being evaluated in LSTM. 
 
Title prospective evaluations of novel RT-PCR assays for the diagnosis of dengue and chikungunya 
Description We have conducted prospective evaluations of novel RT-PCR assays for the diagnosis of dengue and chikungunya in Ecuador, Guatemala and Brazil. The new assays were compared to the reference standard in the national surveillance laboratories (the CDC assays for these viruses). 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact We are currently conducting sequencing of selected samples to confirm our findings. Pending final confirmation, the assays developed (by LSTM in collaboration with Qiagen) are as sensitive and specific as the reference standard 
 
Title safety assessment of the new Genedrive tuberculosis cartridge and reported back to the SME Epistem 
Description The cartridge safety standards were reviewed, which led to a review of procedures and enhancement of the bio-safety of the cartridge. 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact We are currently conducting a new safety evaluation of the cartridge 
 
Title variable immunoglobulin gene region 
Description Sequences of variable region of immunoglobulin genes from individuals living in malaria endemic areas. Enriched for variable immunoglobulin region specific for PfEMP1. Further V(D)J gene regions have been added 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? No  
Impact The data once deposited into a publicly available database will allow comparison with sequences specific for other antigens 
 
Description Avacta 
Organisation Avacta Group
Country United Kingdom 
Sector Private 
PI Contribution Contacts made following Adhiron CiC project and meeting held in Leeds for networking Adhiron technology. Avacta have interests in venoms,thus connections made with Dr Harrison and Venom Research Unit to develop reserach project
Collaborator Contribution Avacta are preparing MOU and in IP nergotiations to prepare the ground for funding of a venom reserach project
Impact Confidentiality agreement
Start Year 2015
 
Description Characterisation of antibody epitopes on CIDRa1 domains 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution My team identified recombinant monoclonal antibodies that cross-react with CIDRa1 domains of PfEMP1, associated with severe malarial disease.
Collaborator Contribution The collaborating team are undertaking structural analysis of the antibody binding sites on PfEMP1
Impact The collaboration resulted in a joint grant application which was not successful. We are now looking at other funding opportunities while generating prelimminary data
Start Year 2018
 
Description Collaboration with Epistem for the development of a prototype HIV/TB integrated cartridge 
Organisation Epistem
Country United Kingdom 
Sector Private 
PI Contribution After review of the literature and identification of international databases, LSTM conducted a target selection for HIV amplification and the design of prototype reagents. Set up of HIV culture at LSTM including HIV-1 and HIV-2. 'Wet reagents' for prototype primers will be tested on cultured samples of HIV from both HIV-1 and HIV-2. Limits of Detection will be calculated. Specificity of primer sets will be assessed by testing samples of Streptococcus pneumoniae and influenza in sputum and hepatitis B and Epson Barr Virus in blood. Pilot collection of clinical samples from Zankli Medical Centre, Nigeria. Pilot samples will be collected from HIV and TB suspects.
Collaborator Contribution Primers and probes will be designed on a high copy number gene target in collaboration with Epistem's team in Manchester. Conduct testing of Epistem's integrated cartridge on TB isolates in Cat 3 facilities. Including biosafety evaluation of specimen handling and Limit of Detection testing.
Impact The output of this project is the joint development of a prototype HIV/TB integrated cartridge in order that funding from other donors can be leveraged for continued product development and evaluation. This would include the quantification of viral load, and further investigation into TB drug resistance markers (isoniazid). LSTM gained major experience with diagnostic development, HIV culturing and long term collaboration with Epistem, including matched funding for the project. Further we aimed to collaborate with our industrial partner Epistem to test sensitivity, specificity, biosafety and development studies in Nigeria of the Mark I cartridge in development.
Start Year 2014
 
Description Collaborators on the 'TB subunit vaccines' project 
Organisation University of Oxford
Department Jenner Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Public Health England at Porton Down were responsible for amplification of desired vaccine candidates and generating the DNA vaccines.
Collaborator Contribution University of Southampton collaborators devised the Reverse Vaccinology approach which led to the selection of the truly novel vaccine candidates for Mycobacterium tuberculosis. Jenner Institute, Oxford University undertook the animal challenge assays to test the efficacy of the DNA vaccines.
Impact Applications for follow-on funding have been made - these were not successful but future funding will be sought. Presentations of the research so far have been made. The collaboration is multi-disciplinary in the fields of bioinformatics, pre-clinical vaccinology and clinical TB vaccine research.
Start Year 2014
 
Description Collaborators on the 'TB subunit vaccines' project 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Public Health England at Porton Down were responsible for amplification of desired vaccine candidates and generating the DNA vaccines.
Collaborator Contribution University of Southampton collaborators devised the Reverse Vaccinology approach which led to the selection of the truly novel vaccine candidates for Mycobacterium tuberculosis. Jenner Institute, Oxford University undertook the animal challenge assays to test the efficacy of the DNA vaccines.
Impact Applications for follow-on funding have been made - these were not successful but future funding will be sought. Presentations of the research so far have been made. The collaboration is multi-disciplinary in the fields of bioinformatics, pre-clinical vaccinology and clinical TB vaccine research.
Start Year 2014
 
Description Drug Discovery Project to develop combination partners targeting the respiratory chain of Mycobacterium tuberculosis 
Organisation Janssen Research & Development
Country Global 
Sector Private 
PI Contribution Novel strategy to improve the efficacy of bedaquiline and NCE
Collaborator Contribution Janssen have provided Materials e.g. bedaquiline. Discussions are taking place for a formal partnership and funding by Janssen of project as well as exclusive licensing of LSTM IP to Janssen.
Impact No outputs as yet
Start Year 2015
 
Description E209 - New Antimalarial Drug 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution Invention of the lead molecule and carrying out of initial biology of a new antimalarial drug.
Collaborator Contribution Formal preclinical evaluation
Impact None as yet
Start Year 2015
 
Description ELISHA 
Organisation Elisha Systems Ltd
Country United Kingdom 
Sector Private 
PI Contribution Developed from Adhiron MRC CiC networking meeting in Leeds. Collaborated in preparing MRC and BBSRC GCRF applications for IQK development.
Collaborator Contribution Contntributed technical input for joint funding applications
Impact Preproposals submitted to BBSRC and MRC GCRF 2016 funding call.
Start Year 2016
 
Description Generation of human monoclonal antibodies against malarial antigens 
Organisation Biomedical Primate Research Centre
Department Department of Parasitology
Country Netherlands 
Sector Academic/University 
PI Contribution Provision of recombinant human monoclonal antibodies specific for domains of PfEMP1
Collaborator Contribution Support in the analysis of adhesion blocking and reversing properties of recombinant human monoclonal antibodies
Impact None to date
Start Year 2014
 
Description Generation of human monoclonal antibodies against malarial antigens 
Organisation University of Oxford
Department Jenner Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Exchange of techniques for the generation of recombinant monoclonal antibodies
Collaborator Contribution Exchange of techniques for the generation of recombinant monoclonal antibodies
Impact Generation of five recombinant monoclonal antibodies that cross-react with variants of the DBLb domain of PfEMP1
Start Year 2014
 
Description Generation of recombinant human monoclonal antibodies targetting the CIDRa1 domain of PfEMP1 
Organisation University of Copenhagen
Department Department of Immunology and Microbiology
Country Denmark 
Sector Academic/University 
PI Contribution We are collaborating on the identification of individuals with broadly cross-reactive antibodies against the CIDRa1 domain of PfEMP1, linked to the pathology of severe malaria. My team has established methods to isolate CIDRa1-specific memory B cells and after single cell sorting, clone and express recombinant monoclonal antibodies.
Collaborator Contribution The Lavstsen team is testing the antibodies that we generated for binding to a wide range of CIDRa1 domains and inhibition of binding to EPCR
Impact To date the collaboration has resulted in joint grant applications. The collaboration resulted in collaborative visits between the two Institutions as well as training of UoC staff in techniques related to isolation of antigen-specific memory B cells at LSTM in 2018.
Start Year 2016
 
Description India-UK Industry partnership 
Organisation Godrej Consumer Products Limited
Country India 
Sector Private 
PI Contribution Presented research and training opprtunities for LSTM-Godrej partnership in the vector control arena. Led to joint applications for MRC CiC award and signing of CDA to pursue technology development optiions
Collaborator Contribution Godrej set up meetings in Mumbai for reserach and training discussions, and intriductions to senior management.
Impact Outcome: 1. application for joint MRC CiC award in 2015 to develop resistance diagnostics 2. Visit planned by Director of LSTM to Godrej headquarters for high level discussions on LSTM-Godrej partnership options
Start Year 2014
 
Description Novel antibiotic nano formulations 
Organisation Blueberry Therapeutics
Country United Kingdom 
Sector Private 
PI Contribution Imaging and PK-PD platform to screen novel antibiotic formulations against Salmonella
Collaborator Contribution nano-formulation expertise and materials
Impact none yet
Start Year 2015
 
Description QuantuMDx 
Organisation QuantuMDx Group Limited
Country United Kingdom 
Sector Private 
PI Contribution LSHTM role was to provide parasite material for use in the QuantuMDx platform device. This involved generating inocula of known number to generate Proof of Principle data in the new technology (a point-of-care diagnostic platform for Leishmania).
Collaborator Contribution QuantuMDx provided the novel platform and cartridges and the SOPs used previously for other indications.
Impact QuantuMDx was to be mostly involved in the last phase of the project when the prototype cartridges had been produced. At the time of project completion this was not ready for the Leishmania cartridge. However, we did evaluate a prototype DNA extraction kit developed by QuantumDx which would simplify the processing of samples.
Start Year 2014
 
Title Combination Therapy 
Description Novel design of Combination Therapy for Tuberculosis drugs based on the inhibition of respiratory inhibitors. TheUK patent application has been submitted and the number is 1522232.6 The patent has been submitted and Janssen Pharmaceutica are interested in an exclusive licence - discussion are underway 
IP Reference GB1522232.6 
Protection Patent application published
Year Protection Granted
Licensed No
Impact The patent has been submitted and Janssen Pharmaceutica are interested in an exclusive licence
 
Title MOSQUITO BED NET ASSEMBLY 
Description Mosquito bed net assembly 10a-h includes a mosquito bed net (12) impregnated with a first insecticide and a barrier member 16a-h located above an upper surface (14) of the bed net (12) and being impregnated with a second insecticide. In use, bed net assembly 16a-h increases the likelihood of delivering a lethal dosage of insecticide to mosquitoes flying in frequently-visited areas of a bed net, without increased attendant health risk to a user. 
IP Reference WO2015063455 
Protection Patent application published
Year Protection Granted 2015
Licensed Yes
Impact None yet.
 
Description Conference "Mosquito-borne viruses: can we build on commonalities to pre-empt the future?" the Wellcome Trust, London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Conference titled "Mosquito-borne viruses: can we build on commonalities to pre-empt the future?" on 5-7 October 2016, London. A joint WHO-Wellcome Trust three-day meeting on mosquito-borne viral diseases; I was a session chair and presenter.

The Wellcome Trust hosted this WHO conference in London, UK on October 5th to 7th 2016. The meeting covered a variety of topics concerning mosquito born viruses, including vaccines, vector control, medicines and blood products, diagnostics, regulatory issues, and yellow fever. An executive summary is now available on request and an official synopsis of this meeting will be published in early 2017.

Attendance by and conversations with DfID staff, are believed to have influenced the prioritising of Aedes-borne arboviral diseases in the 2017 subsequent funding call.
Year(s) Of Engagement Activity 2016
 
Description Discussion forum at the House of Commons 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Dengue: falling between the cracks: a high-level roundtable discussion with Dods and Malaria Consortium, Hosted by Imran Hussain MP at the House of Commons, Wednesday 30th November 2016
Year(s) Of Engagement Activity 2016
 
Description Institutional visit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited Speaker at the University of Saarland, Saarbrucken, Germany
Year(s) Of Engagement Activity 2017
 
Description Institutional visit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited Speaker at the Helmholtz Centre for Infection Research in Braunschweig, Germany
Year(s) Of Engagement Activity 2017
 
Description Invited Speaker at the "Closing the Global Health Divide through Partnership Driven Innovation Meeting" 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The event represented a collective call for greater cross-border and cross-sector collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases that disproportionally affect the poorest of the poor in developing countries. A series of presentations and interactive panels articulated the need for partnerships in global health and explored the challenges associated with R&D for infectious diseases.
Year(s) Of Engagement Activity 2014
 
Description Liverpool Life Sciences UTC, Malaria Seminar Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact 22nd Oct 2014, Liverpool Life Sciences UTC, Malaria Seminar Day. "Malaria: of mosquitoes and men". >100 pupuils from UTC attended a Malaria Seminar Day at U of Liverpool. There was keen interest in the topic with tweets and students following up with visits to the Vector Department to discuss posters and projects.
Year(s) Of Engagement Activity 2014
 
Description MRC Confidence in Concept (CiC) Tropical Infectious Disease Consortium Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact MRC Confidence in Concept (CiC) Tropical Infectious Disease Consortium meeting was held in Oxford on Wednesday 10th February 2016. Attendees included representatives from The MRC, Public Health England, SMEs and several academic Institutions accross the UK. Work on vaccine dose reduction was presented as one of "Showcase presentations" of projects funded by the MRC CiC scheme.

Aims of the meeting were:
- To showcase breadth and depth of projects, highlighting those that have already made significant progress/success
- To discuss further opportunities for cross-institute collaborations
- For the MRC to inform awardees and interested parties of pathways to further funding (e.g. DPFS/TSB etc)
- Foster interaction with SMEs that may be interested in working in partnership with the Consortium to facilitate product funding/development
Year(s) Of Engagement Activity 2016
URL http://www.jenner.ac.uk/_asset/file/mrc-cic-tropical-infectious-disease-consortium-poster-10-feb-16-...
 
Description Poster presentation by PhD student Hisham Alharbi 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Poster presentation of results at the 13th BioMalPar Conference in Heidelberg Germany. The presentation resulted in new collaborations with Matt Higgins, University of Oxford
Year(s) Of Engagement Activity 2017
URL https://www.embl.de/training/events/2017/BMP17-01/
 
Description Presentation 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Presentation to Bill Gates (BMGF), George Osborne (Chancellor for the Exchequer, UK Gov), Justine Greening (DfID, UK), Industry heads and media reps, during institution visit to announce the £3billion Ross Fund.
Year(s) Of Engagement Activity 2016
 
Description Presentation at the IGH, UNITAID and WHO in Madrid 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Presentation entitled "Improved vector control tools from vector behaviour studies" at Bringing innovation to the front line: new tools to advance the global response to vector-borne disease: Institute for Global Health, UnitAid and WHO, Madrid, Spain; 11-12th May 2017
Year(s) Of Engagement Activity 2017
URL https://www.isglobal.org/en/-/from-pipelines-to-frontlines-innovative-tools-to-advance-the-global-re...
 
Description School Visit, Oxford 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Talk on Malaria, Ebola and Vaccines to 130 Year 6 pupils followed by questions afterwards.
Year(s) Of Engagement Activity 2015
 
Description Series of Rational Drug Discovery lectures (Undergraduate) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Undergraduate students
Results and Impact To provide a better understanding how the students can translate their science / research activities to have more impact in terms of generating and developing products such as drugs, insecticides etc.
Year(s) Of Engagement Activity 2018
 
Description Series of rational drug discovery lectures (Post Graduate) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact To provide a better understanding how the students can translate their science / research activities to have mor eimpact in terms of generating and developing products such as drugs, insecticides etc.
Year(s) Of Engagement Activity 2018
 
Description Talk Rotary Club Heswall 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Talk given to Rotary club Members about the reasons behind repeated infection with malaria. Sparked debate and iterest and helped audience to understand why it is so difficult to eradicate the disease
Year(s) Of Engagement Activity 2015